文献类型：期刊文献

英文题名：F-18-FDG PET/CT imaging for aggressive melanotic schwannoma of the L3 spinal root A case report

作者：Shen, Xun-Ze[1];Wang, Wei[2];Luo, Zhou-Ye[1]

机构：[1]Shaoxing Univ, Shaoxing Peoples Hosp, PET CT Ctr, Affiliated Hosp 1, 568 Zhongxing North Rd, Shaoxing City, Peoples R China;[2]Zhejiang Prov Peoples Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China

年份：2021

卷号：100

期号：8

外文期刊名：MEDICINE

收录：SCI-EXPANDED(收录号：WOS:000658985900061)、、WOS

语种：英文

外文关键词：aggressive; fluorodeoxyglucose positron emission tomography; computed tomography; liver; melanotic schwannoma; spinal

外文摘要：Rationale: Melanotic schwannoma (MS) is an unusual variant of a nerve sheath neoplasm that accounts for less than 1% of all primary peripheral nerve sheath tumors. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG PET/CT) has unique value in detecting malignant MS lesions. To date, only 4 cases of MS with hepatic metastasis have been reported. Herein, we report the fifth case, which is the first reported patient with MS of Asian ethnicity with hepatic metastasis. Patient concerns: A 29-year-old woman with a 1-day history of backache was admitted to our hospital. PET/CT showed a paravertebral heterogeneous soft tissue mass along the spinal nerve at the L2-L3 level with strong FDG uptake, and a nodule with increased FDG uptake in the lateral lobe of the left liver. Diagnosis: A puncture biopsy of the L3 bony destruction and surrounding soft tissue mass was performed. The final diagnosis was spinal MS with hepatic metastasis. Interventions: The patient underwent 6 courses of systemic chemotherapy. Outcomes: The patient did not receive further treatment for half a year after the end of chemotherapy and recovered well. Lessons: Unlike conventional schwannomas, which are completely benign, MS has an unpredictable prognosis. It is thought to have low malignant potential, and the malignant type tends to metastasize. FDG PET/CT has a unique and important value in the differential diagnosis of benign and malignant lesions, in detecting occult metastases, monitoring the treatment response, and assessing the prognosis of MS.